Skip to main content
OpenTrials
Completed

NCT Number: NCT03694041

Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers

This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of APX-115 in healthy males. This study also aims to evaluate the effect of food consumption on the pharmacokinetics of APX-115 and potential interaction between caffeine and APX-115 in healthy males.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Eurofins Optimed

Gières, 38610, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Healthy male subject, aged between 18 and 45 years inclusive
  • Certified as healthy by a comprehensive clinical assessment
  • Normal dietary habits
  • Normal ECG recording on a 12-lead ECG
  • Signing a written informed consent prior to selection

Exclusion:

  • Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic, infectious or ocular disease
  • Frequent headaches and / or migraine, recurrent nausea and / or vomiting
  • Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position
  • Blood donation (including in the frame of a clinical trial) within 2 months before administration
  • General anaesthesia within 3 months before administration
  • Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician
  • Inability to abstain from intensive muscular effort
  • No possibility of contact in case of emergency
  • Any drug intake (except paracetamol or contraception) during the last month prior to the first administration
  • History or presence of drug or alcohol abuse (alcohol consumption > 30 grams / day)
  • Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day)
  • Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests
  • Positive results of screening for drugs of abuse
  • Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development
  • Administrative or legal supervision

Treatment and study plan

SAD: APX-115

Drug

Drug: APX-115 SAD APX-115 SAD for 1day

SAD: Placebo

Drug

Drug: Placebo Placebo for 1day

MAD: APX-115

Drug

Drug: APX-115 MAD APX-115 MAD repeatedly administered.

MAD: Placebo

Drug

Matching study drug will be repeatedly administered.

Food effect: fasted and fed

Other

A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.

Metabolic probe with or without APX-115

Other

A metabolic probe will be administered with and without APX-115.

Primary outcomes

  1. SAD: incidence of treatment emergent adverse events

    Time frame: Up to Day 8

  2. SAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)

    Time frame: Up to Day 8

  3. SAD: number of clinically significant abnormal findings from physical exam

    Time frame: Up to Day 8

  4. SAD: number of clinically significant abnormal findings from electrocardiogram

    Time frame: Up to Day 8

  5. SAD: number of clinically significant abnormal findings from biological tests

    Time frame: Up to Day 8

  6. MAD: incidence of treatment emergent adverse events

    Time frame: Up to Day 17

  7. MAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)

    Time frame: Up to Day 17

  8. MAD: number of clinically significant abnormal findings from physical exams

    Time frame: Up to Day 17

  9. MAD: number of clinically significant abnormal findings from electrocardiogram

    Time frame: Up to Day 17

  10. Food effect: peak serum concentration (Cmax) of APX-115 under fasting and fed conditions

    Time frame: Up to Day 4 post-dose

  11. Food effect: time to reach the Cmax (Tmax) of APX-115 under fasting and fed conditions

    Time frame: Up to Day 4 post-dose

  12. Food effect: area under the curve (AUC) of APX-115 under fasting and fed conditions

    Time frame: Up to Day 4 post-dose

  13. Food effect: elimination rate constant (Kel) of APX-115 under fasting and fed conditions

    Time frame: Up to Day 4 post-dose

  14. Food effect: ratio AUCfed/AUCfasted

    Time frame: Up to Day 4 post-dose

  15. Drug interaction: peak serum concentration (Cmax) of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  16. Drug interaction: Time to reach the Cmax (tmax) of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  17. Drug interaction study: Area under the Curve (AUC) of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  18. Drug interaction: elimination rate constant (Kel) of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  19. Drug interaction: half-life (t1/2) of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  20. Drug interaction: volume of distribution (Vd/f) of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  21. Drug interaction: clearance of a metabolic probe or APX-115

    Time frame: Up to Day 4 post-dose

  22. Drug interaction: Incidences of treatment emergent adverse events

    Time frame: Up to Day 4 post-dose

Secondary outcomes

  1. SAD: time to reach Cmax (Tmax) of APX-115

    Time frame: Up to Day 5

  2. SAD: peak serum concentration (Cmax) of APX-115

    Time frame: Up to Day 5

  3. SAD: lowest plasma concentration before next dosing (Ctrough)

    Time frame: Up to Day 5

  4. SAD: Area Under the Curve (AUC) of APX-115

    Time frame: Up to Day 5

  5. SAD: volume of distribution (Vd/F) of APX-115

    Time frame: Up to Day 5

  6. SAD: clearance (CL/F) of APX-115

    Time frame: Up to Day 5

  7. MAD: peak serum concentration (Cmax) of APX-115

    Time frame: Up to Day 11

  8. MAD: time to reach the Cmax (Tmax) of APX-115

    Time frame: Up to Day 11

  9. MAD: Area Under the Curve (AUC) of APX-115

    Time frame: Up to Day 11

  10. MAD: lowest plasma concentration of APX-115 before next dosing (Ctrough)

    Time frame: Up to Day 11

  11. MAD: volume of distribution (Vd/F) of APX-115

    Time frame: Up to Day 11

  12. MAD: Clearance (CL/F) of APX-115

    Time frame: Up to Day 11

  13. MAD: accumulation ratio

    Time frame: Up to Day 11

  14. Food effect & drug interaction: incidence of treatment emergent adverse events

    Time frame: Up to Day 4 post-dose

  15. Food effect & drug interaction: number of clinically significant findings from vital signs (blood pressure and pulse)

    Time frame: Up to Day 4 post-dose

  16. Food effect & drug interaction: number of clinically significant findings from physical exam

    Time frame: Up to Day 4 post-dose

  17. Food effect & drug interaction: number of clinically significant findings from electrocardiogram

    Time frame: Up to Day 4 post-dose

  18. Food effect & drug interaction: number of clinically significant findings from biological tests

    Time frame: Up to Day 4 post-dose

Sponsors and collaborators

Lead sponsor

Aptabio Therapeutics, Inc.

Industry

Registry information

Official study title

Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses or Multiple Ascending Doses of APX-115 in Healthy Male Volunteers.

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Oct 3, 2018
Registry last updated
Mar 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.